ArticlemSystems2024
Genome sequencing unveils
Article in mSystems, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 22 citations in OpenAlex.
- Comparative genomics of hypervirulent Klebsiella pneumoniae isolates from Brazil.Archives of microbiology · 2026Article
- Genomic analysis of MCR-8 and NDM-5 coproducingBiosafety and health · 2026Article
- Early detection of gastric cancer: a novel circulating microbiome DNA based liquid biopsy assay.NPJ precision oncology · 2026Article
- Role of Mobilome in Carbapenem Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Article
- The dynamic distribution of genetic tandem amplifications in a heteroresistant Escherichia coli population revealed by ultra-deep long read sequencing.Nature communications · 2026Article
- The plasmid-host fitness landscape: a new paradigm for predicting the fate of mobile resistance.Applied and environmental microbiology · 2026Review
- Molecular Insights into Carbapenem Resistance inInternational journal of molecular sciences · 2026Review
- Emergence and regional evolution of Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae ST11 in China.BMC genomics · 2025Article
- The applications and advantages of nanopore sequencing in bacterial antimicrobial resistance surveillance and research.npj antimicrobials and resistance · 2025Review
- High transconjugation efficiency of fusion plasmid pNDM_KPC in carbapenem-resistantMicrobiology spectrum · 2025Article
- Rapid Identification and Typing of Carbapenem-Resistant Klebsiella pneumoniae Using MALDI-TOF MS and Machine Learning.Microbial biotechnology · 2025Article
- Carbapenem-resistantMicrobiology spectrum · 2025Article
- TrackingFuture microbiology · 2025Article
- Clinical and Microbiological Characteristics of Carbapenem-ResistantInfection and drug resistance · 2025Article
- In-host co-colonization and bloodstream infection by distinct classical and hypervirulent CRKP clones harboring a homologousFrontiers in cellular and infection microbiology · 2025Article
- Characteristic of KPC-12, a KPC Variant Conferring Resistance to Ceftazidime-Avibactam in the Carbapenem-ResistantInfection and drug resistance · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
Abstract
The threat posed by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.